Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × NSCLC × nimotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Nasopharyngeal Carcinoma 16 Esophageal Squamous Cell Carcinoma 11 Squamous Cell Carcinoma of Head and Neck 8 Esophageal Neoplasms 8 Pancreatic Neoplasms 7 Uterine Cervical Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Head and Neck Neoplasms 5 Pancreatic cancer, adult 2 Neoplasms 2 Nasopharyngeal Neoplasms 2 Lung Neoplasms 2 Colorectal Neoplasms 2 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Anal Canal 1 Solid Tumors 1 Solid Tumor 1 Resectable Pancreatic Cancer 1 Recurrence 1 Penile Neoplasms 1 Pancreatic Cancer Resectable 1 Oropharyngeal Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Diseases 1 NSCLC 1 Meningeal Carcinomatosis 1 Hypopharyngeal Neoplasms 1 HCC 1

Interventions

Drug Therapy 8 osimertinib 7 Pemetrexed 7 Radiotherapy 6 anlotinib 5 Carboplatin 5 Radiosurgery 4 Gefitinib 4 Docetaxel 4 tislelizumab 3 pembrolizumab 3 icotinib 3 aflutinib 3 Vinorelbine 3 Gemcitabine 3 Erlotinib Hydrochloride 3 Cisplatin 3 toripalimab 2 dacomitinib 2 apatinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Paclitaxel 2 Immune Checkpoint Inhibitors 2 Chemotherapy, Adjuvant 2 Chemoradiotherapy 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01861223 2014-02-25

Afatinib Plus Nimotuzumb for NSCLC

Samsung Medical Center

Phase 1/2 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡